Table 3 Connectivity Map compounds with gene expression profiles opposing endometrial cancer risk TWAS associations.

From: Multi-tissue transcriptome-wide association study identifies eight candidate genes and tissue-specific gene expression underlying endometrial cancer susceptibility

Connectivity score

Compound

Drug class

Clinically tested* (highest phase)

Indications

−93.60

Methyl-2,5-dihydroxycinnamate

EGFR inhibitor

No

–

−91.07

Enzastaurin

Protein kinase C inhibitor

Yes (Phase III)

B-cell lymphoma and glioblastoma

−90.09

Prunetin

ABCG2 inhibitor

No

–

−90.00

Nocodazole

Tubulin inhibitor

No

–

  1. *ClinicalTrials.gov database (https://www.clinicaltrials.gov) accessed June 2021.
Back to article page